Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02836899 · ClinicalTrials.gov registry record · Phase 3

Effect of Nitric Oxide in Cardiac Surgery Patients With Endothelial Dysfunction.

A Phase 3 study, sponsored by Massachusetts General Hospital.

Completed
Registry status
Phase 3
Development phase
250
Enrollment target

NCT02836899: Completed Phase 3 study, sponsored by Massachusetts General Hospital.

NCT02836899 is a Phase 3 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 250 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02836899, a Phase 3 study, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
Phase 3
Development phase
250 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether nitric oxide is effective in the treatment of acute kidney injury in cardiac surgical patients with sign and laboratory data suggesting endothelial dysfunction undergoing prolonged cardiopulmonary bypass.

Primary Outcome

Acute kidney injury (AKI) is defined by KDIGO criteria as an abrupt (within 48h) reduction in kidney function correlated to an absolute increase in serum creatinine of 0.3 mg/dL or more (≥26.4 μmol/L) or a percentage increase in serum creatinine of 50% or more (1.5-fold from baseline) at any time during the first 7 days after surgery or, finally, a reduction in urine output with a documented oliguria of \< 0.5 ml/Kg/h for \>6h.

Interventions

  • OTHER Placebo
  • DRUG Nitric Oxide

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2017-02-08
Est. Completion 2025-08-15
Phase Phase 3
Massachusetts General Hospital

2,032 total trials

What the finished NCT02836899 record still lists

NCT02836899 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02836899 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02836899 about?

NCT02836899 is a clinical study titled "Effect of Nitric Oxide in Cardiac Surgery Patients With Endothelial Dysfunction.". The purpose of this study is to determine whether nitric oxide is effective in the treatment of acute kidney injury in cardiac surgical patients with sign and laboratory data suggesting endothelial dysfunction undergoing prolonged cardiopulmonary bypass.

What is the current status of trial NCT02836899?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2017-02-08. Estimated completion is 2025-08-15.

What interventions are being tested in trial NCT02836899?

The interventions under investigation include: Placebo (OTHER), Nitric Oxide (DRUG).

Who is sponsoring clinical trial NCT02836899?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02836899's enrollment target sits among peer trials

250 1249th of 2000 higher than 735 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00483249 · 250 participants · NA

    Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm

  • NCT00777712 · 250 participants

    Mechanisms Underlying Impaired Diabetic Wound Healing

  • NCT01451502 · 250 participants · NA

    Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

  • NCT01771718 · 250 participants

    Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02836899, the US trial registry maintained by the National Library of Medicine. NCT02836899 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.